The Future of Breast Cancer Care: Could a Simple Blood Test Catch Recurrence Earlier?

Image: Collected

A promising new technology known among doctors as a "liquid biopsy" is generating hope among medical professionals, researchers, and patients as a potential breakthrough for detecting breast cancer recurrence earlier. According to a report by ELLE (elleusa), circulating tumor DNA (ctDNA) blood tests could become a vital tool in addressing one of the most challenging gaps in modern breast cancer follow-up care.

Under current realities, nearly 30 percent of women who are diagnosed with early-stage breast cancer ultimately go on to develop metastatic breast cancer, meaning the disease has spread to other parts of the body. Once the cancer spreads beyond its original site, it is classified as stage IV disease. While stage IV breast cancer is treatable, it remains incurable.

Despite the high rate of recurrence, routine proactive scanning is not standard medical practice for patients after initial treatment. Elisa Port, MD, a breast surgeon and author of The Breast Advice: All You Need to Know About Breast Health, Screening, and Treatment, explained to ELLE why standard monitoring does not typically involve preemptive imaging.

"In general, we don’t scan people proactively," Dr. Port stated, noting that "unfortunately, there is no such thing as early-stage IV disease".

To bridge this gap, doctors, researchers, and patients are looking to circulating tumor DNA (ctDNA) blood tests as an easier, non-invasive way to identify a cancer recurrence sooner than traditional methods allow. By using a blood draw to look for tumor DNA, researchers hope this new liquid biopsy technology could hold the key to earlier intervention and reshape the future of breast cancer monitoring.